What is ASBP's relative strength rating?

ASBP ranks at the 66th percentile over 1 month, 93th percentile over 3 months, 3th percentile over 6 months, 2th percentile over 1 year against the full TickerStance CS+ADRC universe of U.S. equities.

What sector is ASBP in?

ASBP is classified under the Healthcare sector within the Pharmaceutical Products industry per the TickerStance sector-classification pipeline, which maps U.S. equities to GICS-aligned sectors using exchange SIC codes and Massive Finance reference data. Healthcare is currently ranked 3 of 11 sectors by relative strength.

Is ASBP in a leading sector?

Yes — Healthcare ranks at the 82th percentile by sector relative strength, placing it in the leading band (≥ 70th percentile). ASBP benefits from positive sector-level momentum, which historically correlates with above-average stock-level RS performance in the O'Neil / Minervini framework.

How volatile is ASBP?

ASBP currently shows a 20-day average daily range (ADR%) of 9.7%, a 90-day beta versus the S&P 500 of 3.87. An ADR% above 4% indicates an intraday swing-trading eligible name in the Minervini Volatility Contraction Pattern framework. ADR% and ATR% are updated daily; beta is computed over a trailing 90-day window.

Does ASBP have a seasonal pattern?

TickerStance computes ASBP's month-by-month seasonality from its full daily price history: the average and median return for each calendar month, how often that month closed higher, and the best and worst months on record. These are historical frequencies, not forecasts — a strong seasonal month describes what ASBP has tended to do in prior years, not a prediction of what comes next. The full month-by-month heatmap and win-rate table sit higher on this page.

When did ASBP last report earnings?

ASBP most recently filed a 10-Q covering FY26 Q2 with the SEC on 2026-08-13. TickerStance sources earnings data from SEC EDGAR XBRL submissions and updates the fundamentals panel daily. The Pro dossier shows eight quarters of EPS and revenue trend, operating margin history, and a composite earnings-quality rank.

Aspire Biopharma Holdings, Inc. Common Stock (ASBP)

TODAY'S READ · AS OF 2026-08-24

As of 2026-08-24, Aspire Biopharma Holdings, Inc. Common Stock (ASBP) has a 3-month relative strength percentile of 93 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 36. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 9.7%, relative volume 1.39×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.

RS methodology →

Market-wide RS; lit = leaderboard

Lenses lit

3 month93pctile

6 month3pctile

1 year2pctile

Classic11IBD pctile

LDR5leadership

0 of 5 lenses lit · avg RS pctile 23

✓ADR%9.7%!A/DE!RVOL1.39×!$ Vol$2M

Market backdrop

47.8Neutral

Trend30% weight44.9 Breadth30% weight50.6 Leadership20% weight42.4 Macro20% weight59.0 Full stance breakdown →

§ Seasonality

10y · since 2025

Best monthOct on averageavg +85.68% · 100% win · n 1

Worst monthNov on averageavg -72.37% · 0% win · n 1

ASBP monthly seasonality strip
	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec
1	ASBP Jan avg: -59.63% median: -59.63% win: 0% σ: 0.00% n: 1 2025-02-21 → 2026-07-31	ASBP Feb avg: -55.20% median: -55.20% win: 0% σ: 28.93% n: 2 2025-02-21 → 2026-07-31	ASBP Mar avg: -43.53% median: -43.53% win: 0% σ: 24.93% n: 2 2025-02-21 → 2026-07-31	ASBP Apr avg: -52.87% median: -52.87% win: 0% σ: 36.27% n: 2 2025-02-21 → 2026-07-31	ASBP May avg: -7.93% median: -7.93% win: 50% σ: 13.26% n: 2 2025-02-21 → 2026-07-31	ASBP Jun avg: -20.09% median: -20.09% win: 0% σ: 24.55% n: 2 2025-02-21 → 2026-07-31	ASBP Jul avg: 31.89% median: 31.89% win: 100% σ: 13.84% n: 2 2025-02-21 → 2026-07-31	ASBP Aug avg: 50.96% median: 50.96% win: 100% σ: 0.00% n: 1 2025-02-21 → 2026-07-31 (current)	ASBP Sep avg: -64.19% median: -64.19% win: 0% σ: 0.00% n: 1 2025-02-21 → 2026-07-31	ASBP Oct avg: 85.68% median: 85.68% win: 100% σ: 0.00% n: 1 2025-02-21 → 2026-07-31	ASBP Nov avg: -72.37% median: -72.37% win: 0% σ: 0.00% n: 1 2025-02-21 → 2026-07-31	ASBP Dec avg: 24.79% median: 24.79% win: 100% σ: 0.00% n: 1 2025-02-21 → 2026-07-31

Evidence · 1 of 3

Receipts behind the read

1 of 5 pass

Leadership

Is it leading?

Relative strength across horizons plus the leadership score.

1m

66

3m

93

6m

3

1y

2

LDR

—

StageWeinstein stage analysis

Stage 4 · Decline✓

Smart money

Who's accumulating?

Accumulation rating, relative volume, U/D ratio, breakout-day proof.

Fundamentals · ASBP

Does the business back the chart?

SEC EDGAR · last filing 10-Q · FY26 Q2 · period end 2026-06-30

—

Fundamentals Growth Rank

How does growth rank vs. the universe?

Insufficient history: EPS 7Q, revenue 3Q (6Q minimum)

View fundamental leadership map

Earnings

Are losses narrowing?

Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.

Loss narrowing

−$0.01—

24 Q3

−$504.88—

25 Q1

−$48.19

Evidence · 2 of 3

Sector context

Healthcare · 82th pctile in sector

Top peers · Healthcare

Who else is leading?

ELOX
99RS 3m
FBRX
99RS 3m
MRNA
99RS 3m
ASBP
93RS 3m · you

Sector vs market

Healthcare · 3 of 11

Energy100

Technology91

Healthcare82

Financials

PEERS · Pharmaceutical Products

Same industry, closest relative strength

4 peers · by RS6M

RNAAtrium Therapeutics, Inc. Common Stock3 BDRXBiodexa Pharmaceuticals plc American Depositary Shs3 RGCRegencell Bioscience Holdings Limited Ordinary Shares3 CNTXContext Therapeutics Inc. Common Stock3

Public attention · ASBP

Is the crowd watching?

11/ 100 · vs its own 90-day norm▼ 34 vs 7dStealth leader

Strong relative strength, but attention is quiet relative to this name’s own recent norm. Academic work links low public attention to better forward returns on average — context to weigh, not a forecast.

Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.

Reference

Company snapshot

SectorHealthcare

IndustryPharmaceutical Products

SIC2834

Float1.0Mshares

Shares out1.4Mshares

Market cap$11.0MNano Cap

FAQ

Frequently asked questions

What is ASBP's relative strength rating?: ASBP ranks at the 66th percentile over 1 month, 93th percentile over 3 months, 3th percentile over 6 months, 2th percentile over 1 year against the full TickerStance CS+ADRC universe of U.S. equities.
What sector is ASBP in?: ASBP is classified under the Healthcare sector within the Pharmaceutical Products industry per the TickerStance sector-classification pipeline, which maps U.S. equities to GICS-aligned sectors using exchange SIC codes and Massive Finance reference data. Healthcare is currently ranked 3 of 11 sectors by relative strength.
Is ASBP in a leading sector?: Yes — Healthcare ranks at the 82th percentile by sector relative strength, placing it in the leading band (≥ 70th percentile). ASBP benefits from positive sector-level momentum, which historically correlates with above-average stock-level RS performance in the O'Neil / Minervini framework.
How volatile is ASBP?: ASBP currently shows a 20-day average daily range (ADR%) of 9.7%, a 90-day beta versus the S&P 500 of 3.87. An ADR% above 4% indicates an intraday swing-trading eligible name in the Minervini Volatility Contraction Pattern framework. ADR% and ATR% are updated daily; beta is computed over a trailing 90-day window.
Does ASBP have a seasonal pattern?: TickerStance computes ASBP's month-by-month seasonality from its full daily price history: the average and median return for each calendar month, how often that month closed higher, and the best and worst months on record. These are historical frequencies, not forecasts — a strong seasonal month describes what ASBP has tended to do in prior years, not a prediction of what comes next. The full month-by-month heatmap and win-rate table sit higher on this page.

Aspire Biopharma Holdings, Inc. Common Stock (ASBP) — Stance & relative strength

Lenses lit

Market backdrop

§ Seasonality

Receipts behind the read

Is it leading?

Who's accumulating?

Does the business back the chart?

Are losses narrowing?

Sector context

Who else is leading?

Healthcare · 3 of 11

Same industry, closest relative strength

Is the crowd watching?

Company snapshot

Frequently asked questions

How much does it move?

Is revenue confirming?

Are margins expanding?

Share count: tailwind or headwind?

§ Seasonality

Aspire Biopharma Holdings, Inc. Common Stock (ASBP) — Stance & relative strength

ASBP is on the watchlist, not confirmed. 3m RS is 93, Market Stance is mixed at 47.8, A/D rating E

Lenses lit

Market backdrop

Receipts behind the read

Is it leading?

Who's accumulating?

Does the business back the chart?

Are losses narrowing?

Sector context

Who else is leading?

Healthcare · 3 of 11

Same industry, closest relative strength

Is the crowd watching?

Company snapshot

Frequently asked questions

How much does it move?

Is revenue confirming?

Are margins expanding?

Share count: tailwind or headwind?